Bionovo, Inc.
5858 Horton Street
Suite 400
Emeryville,
CA 94608
United States - Map
Phone: 510-601-2000
Fax: 510-601-5050
Web Site: http://www.bionovo.com
| Bionovo, Inc., a clinical stage drug discovery and development company, focuses on womens health and cancer primarily in the United States. Its lead drug candidate, Menerba, is a receptor sub-type selective estrogen receptor modulator for the treatment of vasomotor symptoms of menopause. Bionovo, Inc. also develops Bezielle (formerly BZL101), an oral anti-cancer agent for advanced breast cancer, as well as Seala (formerly VG101), a preclinical drug candidate for the treatment of post-menopausal vulvar and vaginal atrophy. The company was founded in 2002 and is based in Emeryville, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Isaac Cohen L.Ac., O.M.D., 47
Co-Founder, Chairman, Chief Exec. Officer and Chief Scientific Officer |
$
373.00K |
$
0 | Dr. Mary Tagliaferri M.D., L.Ac., 44
Co-Founder, Pres, Chief Medical Officer, Chief Regulatory Officer, Medical Director, Sec., Treasurer |
$
373.00K |
$
0 | Mr. Thomas C. Chesterman M.B.A., 50
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Sr. VP and Assistant Sec. |
$
319.00K |
$
0 | Dr. Uwe Christians M.D., Ph.D.,
Member of Scientific Advisory Board and Head of Laboratory at Fitzsimmons Biotechnology Park |
N/A
| N/A | Dr. Klaus D. Kohl Ph.D., 59
Chief Technical Officer and Sr. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.27% Nasdaq 
0.01 (1.92%) 
Profile
